|
|
Post by sportsrancho on Oct 11, 2021 5:06:37 GMT -5
|
|
|
|
Post by hellodolly on Oct 11, 2021 8:29:16 GMT -5
ADVERSE REACTIONS Pulmonary Arterial Hypertension (WHO Group 1) In a 12-week, placebo-controlled study (TRIUMPH I) of 235 patients with PAH (WHO Group 1 and nearly all NYHA Functional Class III), the most common adverse reactions seen with TYVASO in ≥4% of PAH patients and more than 3% greater than placebo in the placebo-controlled study were cough (54% vs 29%), headache (41% vs 23%), throat irritation/pharyngolaryngeal pain (25% vs 14%), nausea (19% vs 11%), flushing (15% vs <1%), and syncope (6% vs <1%). In addition, adverse reactions occurring in ≥4% of patients were dizziness and diarrhea. Pulmonary Hypertension Associated with ILD (WHO Group 3) In a 16-week, placebo-controlled study (INCREASE) of 326 patients with PH-ILD (WHO Group 3), adverse reactions were similar to the experience in studies of PAH. Please see Full Prescribing Information, the TD-100 and TD-300 TYVASO® Inhalation System Instructions for Use manuals, and other additional information at www.tyvaso.com or call 1-877-UNITHER (1-877-864-8437). TYVISIhcpAPR2021 Thank you @sportsrancho I don't see a need to add a blackbox warning based on these findings but, I'm not sure how far down the chain the FDA lists non-linked lung cancer to coughing, headaches, throat irritation, nausea and fainting. |
|
|
|
Post by mymann on Oct 15, 2021 13:59:48 GMT -5
Tik tok, Tik tok, The suspense is killing me! Any of you learned and experienced scholars can reassure me? Thanks.
|
|
|
|
Post by winner on Oct 15, 2021 14:08:19 GMT -5
All I can say is I went looking and found approx. $200.00 in the sofa cushions. 38 MORE SHARES. I BELIEVE. L.O.L.
|
|
